(Q36765510)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

How should postprandial glycemia be treated? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

G Charpentier

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

D Dardari

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J P Riveline

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

32 Spec No2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

2S21-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Rationale and options for combination therapy in the treatment of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Phases of functional, near-normoglycaemic insulin substitution: what are computers good for in the rehabilitation process in type I (insulin-dependent) diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Protein Content of the Evening Meal and Nocturnal Plasma Glucose Regulation in Type-I Diabetic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2806%2970481-5

7 January 2021

10.1016/S1262-3636(06)70481-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17375403%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference